Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter van der Meer

Showing results (21-30 of 418) with videos related to

Pageof 42
Sort By:
Journal of the American College of Cardiology|November 27, 2010
Asialoerythropoietin to protect the failing heart: is it possible to run with the hare and hunt with the hounds?Peter van der Meer, Erik Lipsic, Dirk J van Veldhuisen
European Journal of Heart Failure|October 4, 2023
Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long-term survivalAlwin Tubben, Hans L A Nienhuis, Peter van der Meer
European Heart Journal|March 7, 2025
An update on the European Society of Cardiology Council of Cardio-OncologyTeresa López-Fernández, Peter van der Meer, Alexander R Lyon
European Journal of Heart Failure|April 21, 2018
Value of digoxin in patients with heart failure: new pieces to the puzzleDirk J van Veldhuisen, Michiel Rienstra, Peter van der Meer
European Journal of Heart Failure|April 17, 2020
Urinary sodium evaluation: the missing target for diuretic treatment optimization in acute heart failure patients? ReplyKevin Damman, Jozine M Ter Maaten, Peter van der Meer
Nederlands Tijdschrift Voor Geneeskunde|April 20, 2023
[Cardiomyopathy due to a mutation in the phospholamban gene: a high-impact genetic abnormality]Peter van der Meer, Eva van Rooij, Pieter A Doevendans
Current Heart Failure Reports|April 9, 2021
Selenium, Selenoproteins, and Heart Failure: Current Knowledge and Future PerspectiveAli A Al-Mubarak, Peter van der Meer, Nils Bomer
European Journal of Heart Failure|December 8, 2011
Cardiac regeneration in left ventricular dysfunction: are we asking the right questions?Atze van der Pol, Ibrahim Domian, Peter van der Meer
Cardiovascular Therapeutics|October 27, 2010
Erythropoiesis-stimulating agents and heart failureErik Lipšic, Peter van der Meer, Dirk J van Veldhuisen
European Journal of Heart Failure|May 27, 2017
Associations between volume status and circulating microRNAs in acute heart failureEline L Vegter, Peter van der Meer, Adriaan A Voors
Pageof 42

Showing results (21-30 of 418) with videos related to

Sort By:
Pageof 42
Journal of the American College of Cardiology|November 27, 2010
Asialoerythropoietin to protect the failing heart: is it possible to run with the hare and hunt with the hounds?Peter van der Meer, Erik Lipsic, Dirk J van Veldhuisen
European Journal of Heart Failure|October 4, 2023
Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long-term survivalAlwin Tubben, Hans L A Nienhuis, Peter van der Meer
European Heart Journal|March 7, 2025
An update on the European Society of Cardiology Council of Cardio-OncologyTeresa López-Fernández, Peter van der Meer, Alexander R Lyon
European Journal of Heart Failure|April 21, 2018
Value of digoxin in patients with heart failure: new pieces to the puzzleDirk J van Veldhuisen, Michiel Rienstra, Peter van der Meer
European Journal of Heart Failure|April 17, 2020
Urinary sodium evaluation: the missing target for diuretic treatment optimization in acute heart failure patients? ReplyKevin Damman, Jozine M Ter Maaten, Peter van der Meer
Nederlands Tijdschrift Voor Geneeskunde|April 20, 2023
[Cardiomyopathy due to a mutation in the phospholamban gene: a high-impact genetic abnormality]Peter van der Meer, Eva van Rooij, Pieter A Doevendans
Current Heart Failure Reports|April 9, 2021
Selenium, Selenoproteins, and Heart Failure: Current Knowledge and Future PerspectiveAli A Al-Mubarak, Peter van der Meer, Nils Bomer
European Journal of Heart Failure|December 8, 2011
Cardiac regeneration in left ventricular dysfunction: are we asking the right questions?Atze van der Pol, Ibrahim Domian, Peter van der Meer
Cardiovascular Therapeutics|October 27, 2010
Erythropoiesis-stimulating agents and heart failureErik Lipšic, Peter van der Meer, Dirk J van Veldhuisen
European Journal of Heart Failure|May 27, 2017
Associations between volume status and circulating microRNAs in acute heart failureEline L Vegter, Peter van der Meer, Adriaan A Voors
Pageof 42